%0 Journal Article %A J. B. VERMORKEN %A F. LANDONI %A S. PECORELLI %A M. J. PICCART %A M. E. L. VAN DER BURG %A W. W. TEN BOKKEL HUININK %A M. GEORGE %A S. GREGGI %A N. ROTMENSZ %T Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study %D 1991 %R 10.1111/j.1525-1438.1991.tb00050.x %J International Journal of Gynecologic Cancer %P 248-252 %V 1 %N 6 %X Twenty-nine patients with disseminated squamous cell carcinoma of the uterine cervix were treated with a 3 mg/m2 weekly i.v. bolus schedule of vindesine for 6 weeks (thereafter every 2 weeks). Twenty-seven patients were evaluable for response, 19 of whom had received prior chemotherapy (14 also vincristine). Five of the 27 patients (19%) showed a partial response, all being part of the 22 patients with only distant metastases. No objective response were observed among five patients who also had loco-regional recurrent disease. The median duration of response was 21 (11–58) weeks. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. Vindesine warrants further study in combination chemotherapy protocols for cervical cancer. %U https://ijgc.bmj.com/content/ijgc/1/6/248.full.pdf